- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Thyrocare delivered a strong quarter.
**Business Performance:** Consolidated revenue grew 22% YoY to ₹216.53 Cr, fueled by pathology revenue rising 24%. Franchisee revenue climbed 20% to ₹125 Cr, and partnership revenue jumped 35% to ₹66 Cr. The company processed 5.33 crore tests, a 21% YoY increase, serving 5 million patients. Active franchisees expanded 20% to over 10,100. Quality remains robust, with 96% of samples processed in NABL labs.
**Growth Drivers or Strategy:** The company is focusing on deeper penetration into India with a targeted test menu, strengthening its franchise network, and broadening partnerships, including insurance and home ECG services. International expansion in Tanzania is also a key priority, driven by a B2B, affordable value-driven model.
**Recent Developments:** Thyrocare launched a new Regional Processing Lab in Vijayawada, Andhra Pradesh, enhancing its Southern India network. It also held advisory board and channel partner meets to boost relationships and was certified as a 'Great Place To Work.'
**Key Financial Metrics:** Consolidated Reported EBITDA surged 48% YoY to ₹71.45 Cr, with Normalized EBITDA at 35%. Profit After Tax (PAT) soared 82% YoY to ₹47.90 Cr.
**Management Commentary / Outlook:** Management aims to make quality diagnostics affordable for all, reinforcing its strategy as a B2B service provider focused on accessible, high-quality testing.